新一代结肠镜在腺瘤检测方面的优势：一项倾向评分匹配研究。

Advantages of new generation colonoscopes on adenoma detection: A propensity-score matching study.

作者信息

Nishizawa Toshihiro, Toyoshima Osamu, Yoshida Shuntaro, Takahashi Yoshiyuki, Nakagawa Hideki, Mizutani Hiroya, Kataoka Yosuke, Kanazawa Takamitsu, Ebinuma Hirotoshi, Hata Keisuke

机构信息

Department of Gastroenterology and Hepatology, International University of Health and Welfare, Narita Hospital, Narita 286-8520, Japan.

Department of Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan.

出版信息

World J Gastrointest Endosc. 2025 Jun 16;17(6):108146. doi: 10.4253/wjge.v17.i6.108146.

DOI:10.4253/wjge.v17.i6.108146

PMID:40547548

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12179962/

Abstract

BACKGROUND

Recently, Olympus Corporation released new scopes (XZ1200/EZ1500). However, there have been few reports on this topic, although improvement in adenoma detection rate (ADR) by texture and color enhancement imaging (TXI) or computer-aided detection system (CAD) has been reported.

AIM

To investigate the effects of the scope on the detection of adenomas and sessile serrated lesions (SSLs).

METHODS

The subjects were patients who underwent pancolonic chromoendoscopy using the EVIS X1 video system center between May 2023 and October 2024. The patients were divided into the new (CF-XZ1200/CF-EZ1500) and 290 series (CF-HQ290Z/PCF-H290Z) groups. Propensity score matching was performed for age, sex, examination purpose, endoscopist, preparation, TXI use, and CAD use. The effects of the scope were analyzed in terms of the ADR, SSL detection rate (SDR), and mean number of adenomas per colonoscopy (APC).

RESULTS

Of the 7014 patients enrolled, 2138 pairs were extracted by propensity score matching (mean age 55.4 years, 45.5% male). The new scopes group had a significantly higher ADR than the 290 series group [51.5% 45.5%, odds ratio (OR) = 1.27, 95%CI: 1.13-1.43, < 0.001]. Similarly, the new scopes group had significantly higher SDR (7.8% 5.7%, OR = 1.41, 95%CI: 1.11-1.80, = 0.005) and APC (0.90 0.76, OR = 1.11, 95%CI: 1.05-1.17, < 0.001) than the 290 series group.

CONCLUSION

In conclusion, the new scope (CF-XZ1200/CF-EZ1500) enhanced the detection of adenomas and SSLs compared to the old ones (290 series).

摘要

背景

最近，奥林巴斯公司发布了新型内镜（XZ1200/EZ1500）。然而，尽管已有报道称纹理和色彩增强成像（TXI）或计算机辅助检测系统（CAD）可提高腺瘤检出率（ADR），但关于这一主题的报道却很少。

目的

探讨新型内镜对腺瘤和无蒂锯齿状病变（SSLs）检测的影响。

方法

研究对象为2023年5月至2024年10月期间使用EVIS X1视频系统中心进行全结肠色素内镜检查的患者。患者被分为新型内镜组（CF-XZ1200/CF-EZ1500）和290系列组（CF-HQ290Z/PCF-H290Z）。对年龄、性别、检查目的、内镜医师、肠道准备情况、TXI使用情况和CAD使用情况进行倾向得分匹配。从ADR、SSL检出率（SDR）和每次结肠镜检查腺瘤平均数量（APC）方面分析新型内镜的影响。

结果

在纳入的7014例患者中，通过倾向得分匹配提取出2138对（平均年龄55.4岁，男性占45.5%）。新型内镜组的ADR显著高于290系列组[51.5%对45.5%，优势比（OR）=1.27，95%置信区间（CI）：1.13 - 1.43，P<0.001]。同样，新型内镜组的SDR（7.8%对5.7%，OR = 1.41，95%CI：1.11 - 1.80，P = 0.005）和APC（0.90对0.76，OR = 1.11，95%CI：1.05 - 1.17，P<0.001）也显著高于290系列组。